Modular Medical logo

Modular MedicalNASDAQ: MODD

Profile

Sector:

Healthcare

Country:

United States

IPO:

10 February 2022

Next earnings report:

13 November 2024

Last dividends:

N/A

Next dividends:

N/A
$70.99 M
-15%vs. 3y high
39%vs. sector
-vs. 3y high
-vs. sector
-44%vs. 3y high
91%vs. sector
-vs. 3y high
-vs. sector

Price

after hours | Thu, 24 Oct 2024 22:30:34 GMT
$2.18-$0.05(-2.24%)

Dividend

No data over the past 3 years
$200.00 K$100.00 K

Analysts recommendations

Institutional Ownership

MODD Latest News

Modular Medical Announces Conference Call to Discuss FDA Clearance of the MODD1 Insulin Pump
accesswire.com04 September 2024 Sentiment: POSITIVE

SAN DIEGO, CA / ACCESSWIRE / September 4, 2024 / Modular Medical, Inc. (the "Company" or "Modular Medical") (NASDAQ:MODD), an insulin delivery system technology company preparing to launch a market expansion product with a more accessible, easier to prescribe, and easier to pay for and live with technology, today announced it will hold a conference call and webcast tomorrow, Thursday, September 5, 2024, at 8:30 a.m. Eastern Time to discuss the U.

Modular Medical Announces FDA Clearance of the MODD1 Insulin Pump
accesswire.com04 September 2024 Sentiment: POSITIVE

MODD1 is a patch pump for ALL adults with Type 1 and Type 2 diabetes Designed to be simpler and more affordable to expand access to diabetes technology for previously underserved communities Commercial availability expected in early 2025 SAN DIEGO, CA / ACCESSWIRE / September 4, 2024 / Modular Medical, Inc. (the "Company" or "Modular Medical") (NASDAQ:MODD), an insulin delivery system technology company preparing to launch a market expansion product with a more accessible, easier to prescribe, and easier to pay for and live with technology, today announced it has received U. S. Food and Drug Administration ("FDA") clearance to market and sell its MODD1 pump in the United States.

Modular Medical Initiates Transfer of Manufacturing Operations to Phillips Medisize
accesswire.com07 August 2024 Sentiment: POSITIVE

SAN DIEGO, CA / ACCESSWIRE / August 7, 2024 / Modular Medical, Inc. (the "Company" or "Modular Medical") (NASDAQ:MODD), an insulin delivery system technology company preparing to launch the next generation of easy-to-use, prescribe and live with affordable insulin pump technology, today announced it has begun the transfer of its pilot line manufacturing operations to a Phillips Medisize manufacturing site in Queretaro, Mexico. Phillips Medisize, a Molex company, has been an outstanding collaborator in the development of Modular Medical's platform product, supply chain and manufacturing operations, as the Company intends to transition from pre-commercial production to high-volume device manufacturing.

Modular Medical Announces Proof-of-Concept Study for Personalized Metabolic Therapy utilizing the MODD1 Platform
accesswire.com15 July 2024 Sentiment: POSITIVE

Pre-clinical study to explore use of MODD1 pump as a delivery system for FDA-approved, short acting peptides, as a personalized alternative for people who discontinue long-acting GLP-1 formulations SAN DIEGO, CA / ACCESSWIRE / July 15, 2024 / Modular Medical, Inc. (NASDAQ:MODD) ("Modular Medical" or the "Company"), an insulin delivery technology company seeking to launch the next generation of user-friendly and affordable insulin pump technology, today announced a proof-of-concept study with Gubra A/S ("Gubra") in a high-fat, diet-induced obese ("DIO") mouse model to explore the potential future use of the MODD1 pump platform to assist patients who struggle with tolerability, inconsistent efficacy, and cost of long acting GLP-1 therapies. "A recent study published by Blue Health Intelligence using data from a national dataset of private insurers found that about half of all patients prescribed a GLP-1 drug for weight loss discontinued after the first 12 weeks, with approximately 30% discontinuing in the first four weeks," commented Jeb Besser, Chief Executive Officer of Modular Medical.

Modular Medical (MODD) Pairing Technology Issued New U.S. Patent
Zacks Investment Research05 February 2024 Sentiment: POSITIVE

Modular Medical's (MODD) latest U.S. patent is likely to protect the company's technology addressing pairing and allow clinicians to easily upload and review patients' data.

Modular Medical, Inc. (MODD) Forms 'Hammer Chart Pattern': Time for Bottom Fishing?
Zacks Investment Research02 February 2024 Sentiment: POSITIVE

Modular Medical, Inc. (MODD) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term.

What type of business is Modular Medical?

Modular Medical, Inc. operates as a medical device company. It focuses on the design, development, and commercialization of insulin pumps. It offers MODD1, a two-part patch pump for type-1 and type-2 diabetes. The company is headquartered in San Diego, California.

What sector is Modular Medical in?

Modular Medical is in the Healthcare sector

What industry is Modular Medical in?

Modular Medical is in the Medical Devices industry

What country is Modular Medical from?

Modular Medical is headquartered in United States

When did Modular Medical go public?

Modular Medical initial public offering (IPO) was on 10 February 2022

What is Modular Medical website?

https://modular-medical.com

Is Modular Medical in the S&P 500?

No, Modular Medical is not included in the S&P 500 index

Is Modular Medical in the NASDAQ 100?

No, Modular Medical is not included in the NASDAQ 100 index

Is Modular Medical in the Dow Jones?

No, Modular Medical is not included in the Dow Jones index

When was Modular Medical the previous earnings report?

No data

When does Modular Medical earnings report?

The next expected earnings date for Modular Medical is 13 November 2024